#1 Clinical Trials Search in Europe by CTIN

Our offer Newsroom

Find a treatment: By disease

Verifiedinfo

Stichting Meander Medisch Centrum

The Netherlands Maatweg 3, 3813 TZ Amersfoort, The Netherlands

2 trials recruiting
Chronic obstructive pulmonary disease · Acute myocardial infarction · Non-small cell lung cancer
Adult patients

About Specializations

Stichting Meander Medisch Centrum in Amersfoort, The Netherlands specialises in clinical trials of conditions such as Chronic obstructive pulmonary disease, Acute myocardial infarction, Non-small cell lung cancer, Chronic lymphocytic leukaemia, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Diseases

The Cardiology department at Stichting Meander Medisch Centrum is advancing treatment options for patients with atrial fibrillation, focusing on safer anticoagulation to lower the risk of stroke and systemic embolism.

Comparative effectiveness of novel oral anticoagulants
Prevention of cardioembolic events
Safety and tolerability profiling in real‑world settings

These studies aim to refine therapeutic choices and improve long‑term outcomes for individuals at high cardiovascular risk.

Neoplasms

Research in the oncology sphere targets non–small cell lung cancer with a specific focus on tumors that are KRAS p.G12C positive and lack PD‑L1 expression, evaluating the benefit of targeted agents such as sotorasib alongside chemotherapy.

Targeted therapy for KRAS‑mutated lung cancer
Combination strategies with immunotherapy
Biomarker‑driven treatment selection

The goal is to enhance progression‑free survival and overall survival by personalizing treatment pathways for advanced disease patients.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Maatweg 33813 TZ AmersfoortThe Netherlands

Open in maps ↗

Recruiting now: 2 trials
Conditions studied: 13
Partner status: Verified

More sites in Amersfoort The Netherlands

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

12 clinical trials

Acute myocardial infarction

Recruiting

Investigational

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:Selatogrel
Sponsor:Viatris Innovation GmbH

Contact Research Centre

Non-small cell lung cancer

Recruiting

Registered drugNo placebo

Comparing Sotorasib and Pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Amgen Inc.

Contact Research Centre

Chronic lymphocytic leukaemia+1

Not yet recruiting

Registered drugNo placebo

Study of pirtobrutinib plus epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Epcoritamab
Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Contact Research Centre

Acute myeloid leukaemia

Not yet recruiting

Registered drugNo placebo

Study on the Safety of Ivosidenib and Azacitidine for Adults with Newly Diagnosed IDH1m Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Azacitidine
Sponsor:Servier Affaires Medicales

Contact Research Centre

Arteriosclerosis

Not recruiting

Investigational

A study to evaluate the effect of olpasiran on major cardiovascular events in patients with atherosclerotic cardiovascular disease and high levels of lipoprotein(a)

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Sponsor:Amgen Inc.

Contact Research Centre

Chronic obstructive pulmonary disease

Not recruiting

Investigational

Study on Benralizumab for Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with Frequent Exacerbations

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:Benralizumab
Sponsor:AstraZeneca AB

Contact Research Centre

Chronic obstructive pulmonary disease

Not recruiting

Investigational

Study of Astegolimab Treatment in Patients with Chronic Obstructive Pulmonary Disease (COPD) to Reduce Disease Flare-ups

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:Astegolimab
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Acute coronary syndrome

Not recruiting

Registered drug

Study on Milvexian and Drug Combination for Patients Recovering from a Heart Attack

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Acetylsalicylic Acid
Sponsor:Janssen - Cilag International

Contact Research Centre

Atrial fibrillation

Not recruiting

Registered drug

Study on Milvexian and Apixaban for Preventing Stroke in Patients with Atrial Fibrillation

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Andexanet Alfa
Sponsor:Janssen - Cilag International

Contact Research Centre

Diffuse large B-cell lymphoma

Not recruiting

Registered drugNo placebo

Study on the Safety and Effectiveness of Epcoritamab with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Cyclophosphamide
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Type IIa hyperlipidaemia

Not recruiting

Investigational

Study on the Effectiveness of Enlicitide Chloride in Reducing Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Non-small cell lung cancer stage I+1

Not recruiting

Registered drug

Study on the Safety and Effectiveness of Stereotactic Body Radiotherapy with or without Pembrolizumab for Patients with Unresected Stage I or II Non-Small Cell Lung Cancer

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.